WASOFF EVAN L (Chief Financial Officer) received a stock award from NEXIEN BIOPHARMA, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 4/5/2021ACC: 0001214659-21-003944
Officer· Chief Financial Officer
Since Jul 2018
+1M
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
1
Total transactions
1M acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+1M
Price / share
—
Trade value
—
% of position
100.0%
4/1/2021
1M→2M
Total
Net shares
+1M
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 4/1/2021 | A · Award | +1M | — | — | 100.0% | 1M | 2M |
| Total | +1M | $0.00 | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)0
No non-derivative holdings reported
Derivative Holdings (Post-Transaction)3
Stock option - right to buy
DirectUnderlying security
Common Stock
Underlying shares
200K
Shares owned
200K
Exercise price
0.655
Expiration
—
Exercise window
—
Stock option - right to buy
DirectUnderlying security
Common Stock
Underlying shares
420K
Shares owned
420K
Exercise price
0.54
Expiration
—
Exercise window
—
Options to purchase common stock (right to buy)
DirectUnderlying security
Common Stock
Underlying shares
1.50M
Shares owned
1.50M
Exercise price
0.08
Expiration
—
Exercise window
—
Total
Underlying
2.12M
Owned
2.12M
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Stock option - right to buy Direct | Common Stock | 0.655 | — | — | 200K | 200K |
| Stock option - right to buy Direct | Common Stock | 0.54 | — | — | 420K | 420K |
| Options to purchase common stock (right to buy) Direct | Common Stock | 0.08 | — | — | 1.50M | 1.50M |
| Total | 2.12M | 2.12M | ||||